Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (2): 155-161.doi: 10.7518/gjkq.2018.02.007
• Oral Medicine • Previous Articles Next Articles
Yao Yihuan, Wang Jiongke, Zhao Kui, Shi Yujie, Zeng Xin, Chen Qianming
CLC Number:
| [1] Bystryn JC.Adjuvant therapy of pemphigus[J]. Arch Dermatol, 1984, 120(7):941-951. [2] 江潞, 陈谦明. 天疱疮的糖皮质激素治疗[J]. 国外医学口腔医学分册, 2004, 31(6):478-480. Jiang L, Chen QM.The glucocorticoid therapy of pemphigus[J]. Foreign Med Sci: Stomatol, 2004, 31(6):478-480. [3] Rosenberg FR, Sanders S, Nelson CT.Pemphigus: a 20-year review of 107 patients treated with cortico-steroids[J]. Arch Dermatol, 1976, 112(7):962-970. [4] Schiavo AL, Puca RV, Ruocco V, et al.Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies[J]. Clin Dermatol, 2010, 28(3):337-343. [5] Meurer M.Immunosuppressive therapy for autoim-mune bullous diseases[J]. Clin Dermatol, 2012, 30(1):78-83. [6] Sandborn WJ.State-of-the-art: immunosuppression and biologic therapy[J]. Dig Dis, 2010, 28(3):536-542. [7] Anstey AV, Wakelin S, Reynolds NJ, et al.Guidelines for prescribing azathioprine in dermatology[J]. Br J Dermatol, 2004, 151(6):1123-1132. [8] Weinshilboum RM, Sladek SL.Mercaptopurine phar-macogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity[J]. Am J Hum Genet, 1980, 32(5):651-662. [9] Hertl M, Jedlickova H, Karpati S, et al.Pemphigus. S2 guideline for diagnosis and treatment—guided by the European Dermatology Forum (EDF) in co-operation with the European Academy of Dermato-logy and Venereology (EADV)[J]. J Eur Acad Der-matol Venereol, 2015, 29(3):405-414. [10] Committee for Guidelines for the Management of Pemphigus Disease, Amagai M, Tanikawa A, et al. Japanese guidelines for the management of pemphi-gus[J]. J Dermatol, 2014, 41(6):471-486. [11] Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al.Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris[J]. J Am Acad Dermatol, 2007, 57(4):622-628. [12] Esmaili N, Chams-Davatchi C, Valikhani M, et al.Assessment of the therapeutic benefit of oral predni-solone and common adjuvant therapy in stage Ⅱ of randomized controlled trial study for management of pemphigus vulgaris[J]. Arch Iran Med, 2014, 17(9): 626-628. [13] Chams-Davatchi C, Mortazavizadeh A, Daneshpa-zhooh M, et al. Randomized double blind trial of pre-dnisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris[J]. J Eur Acad Dermatol Venereol, 2013, 27(10):1285-1292. [14] Aberer W, Wolff-Schreiner EC, Stingl G, et al.Aza-thioprine in the treatment of pemphigus vulgaris. A long-term follow-up[J]. J Am Acad Dermatol, 1987, 16(3 Pt 1):527-533. [15] Younger IR, Harris DW, Colver GB.Azathioprine in dermatology[J]. J Am Acad Dermatol, 1991,25(2 Pt 1):281-286. [16] Doukaki S, Pistone G, Aricò M, et al.Pharmacoki-netic evaluation of mycophenolate mofetil for pem-phigus[J]. Expert Opin Drug Metab Toxicol, 2011, 7(2):237-244. [17] Doukaki S, Platamone A, Alaimo R, et al.Mycophe-nolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus[J]. J Dermatolog Treat, 2015, 26(1):67-72. [18] Beissert S, Werfel T, Frieling U, et al.A comparison of oral methylprednisolone plus azathioprine or myco-phenolate mofetil for the treatment of pemphigus[J]. Arch Dermatol, 2006, 142(11):1447-1454. [19] Beissert S, Mimouni D, Kanwar AJ, et al.Treating pemphigus vulgaris with prednisone and mycophe-nolate mofetil: a multicenter, randomized, placebo-controlled trial[J]. J Invest Dermatol, 2010, 130(8): 2041-2048. [20] Ioannides D, Apalla Z, Lazaridou E, et al.Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study[J]. J Eur Acad Dermatol Venereol, 2012, 26(7):855-860. [21] Fleming RA.An overview of cyclophosphamide and ifosfamide pharmacology[J]. Pharmacotherapy, 1997, 17(5 Pt 2):146S-154S. [22] Sharma VK, Khandpur S.Evaluation of cyclophos-phamide pulse therapy as an adjuvant to oral cortico-steroid in the management of pemphigus vulgaris[J]. Clin Exp Dermatol, 2013, 38(6):659-664. [23] Rose E, Wever S, Zilliken D, et al.Intravenous dexa-methasone-cyclophosphamide pulse therapy in com-parison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a mul-ticenter prospectively randomized study[J]. J Dtsch Dermatol Ges, 2005, 3(3):200-206. [24] Sethy PK, Khandpur S, Sharma VK.Randomized open comparative trial of dexamethasone-cyclopho-sphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral pred-nisolone in pemphigus vulgaris[J]. Indian J Dermatol Venereol Leprol, 2009, 75(5):476-482. [25] Talar-Williams C, Hijazi YM, Walther MM, et al.Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis[J]. Ann Intern Med, 1996, 124(5):477-484. [26] Cummins DL, Mimouni D, Anhalt GJ, et al.Oral cyc-lophosphamide for treatment of pemphigus vulgaris and foliaceus[J]. J Am Acad Dermatol, 2003, 49(2): 276-280. [27] Damiano S, Ciarcia R, Montagnaro S, et al.Prevention of nephrotoxicity induced by cyclosporine-A: role of antioxidants[J]. J Cell Biochem, 2015, 116(3):364-369. [28] Lapidoth M, David M, Ben-Amitai D, et al.The effi-cacy of combined treatment with prednisone and cyc-losporine in patients with pemphigus: preliminary study[J]. J Am Acad Dermatol, 1994, 30(5 Pt 1):752-757. [29] Mobini N, Padilla T Jr, Ahmed AR.Long-term re-mission in selected patients with pemphigus vulgaris treated with cyclosporine[J]. J Am Acad Dermatol, 1997, 36(2 Pt 1):264-266. [30] Ioannides D, Chrysomallis F, Bystryn JC.Ineffec-tiveness of cyclosporine as an adjuvant to cortico-steroids in the treatment of pemphigus[J]. Arch Der-matol, 2000, 136(7):868-872. [31] Genestier L, Paillot R, Quemeneur L, et al.Mecha-nisms of action of methotrexate[J]. Immunopharma-cology, 2000, 47(2/3):247-257. [32] Gürcan HM, Ahmed AR.Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid[J]. Br J Dermatol, 2009, 161(4): 723-731. [33] Tran KD, Wolverton JE, Soter NA.Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients[J]. Br J Dermatol, 2013, 169(4):916-921. [34] Harman KE, Albert S, Black MM, et al.Guidelines for the management of pemphigus vulgaris[J]. Br J Dermatol, 2003, 149(5):926-937. [35] Cronstein BN.Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis[J]. Pharmacol Rev, 2005, 57(2):163-172. [36] Shah N, Green AR, Elgart GW, et al.The use of chlo-rambucil with prednisone in the treatment of pem-phigus[J]. J Am Acad Dermatol, 2000, 42(1 Pt 1): 85-88. [37] Sugita K, Hirokawa H, Izu K, et al.D-penicillamine-induced pemphigus successfully treated with combi-nation therapy of mizoribine and prednisolone[J]. J Dermatolog Treat, 2004, 15(4):214-217. [38] Turka LA, Dayton J, Sinclair G, et al.Guanine ribo-nucleotide depletion inhibits T cell activation. Me-chanism of action of the immunosuppressive drug mizoribine[J]. J Clin Invest, 1991, 87(3):940-948. [39] Dastgheib L, Sadati MS, Baghernejhad M.Assess-ment of the adjuvant effect of tacrolimus in the ma-nagement of pemphigus vulgaris: a randomized con-trolled trial[J]. J Dermatolog Treat, 2015, 26(1):90-93. [40] Büsing V, Kern JS, Bruckner-Tuderman L, et al.Re-calcitrant pemphigus vulgaris responding to systemic tacrolimus[J]. Dermatology, 2010, 221(2):122-126. [41] Cohen SN, Lim RP, Paul CJ, et al.Equal efficacy of topical tacrolimus and clobetasone butyrate in pem-phigus foliaceus[J]. Int J Dermatol, 2006, 45(11): 1379. |